Kornimate/medical-research-clean huggingface dataset:
the role of cognitive control in the transdiagnostic conceptualization of "intrusive thoughts"

Conditions: Obsessive-Compulsive Disorder; Generalized Anxiety Disorder; Major Depressive Disorder

Summary: the investigators are examining whether difficulties with cognitive control (i.e., the ability to stop one's thought process and shift attention) is a common problem across three types of repetitive, negative thinking: obsessions (as seen in obsessive compulsive disorder, ocd), worries (as seen in generalized anxiety disorder, gad), and ruminations (as seen in major depressive disorder, mdd).

the primary aims of this study are to utilize self-report and behavioral measures to examine whether cognitive control is a common factor across three types of repetitive negative thinking (rnt): obsessions in ocd, worries in gad, and ruminations in mdd. specifically, the investigators aim to test whether individuals with obsessions, worries, and depressive ruminations demonstrate impaired cognitive control on executive functioning neuropsychological tasks (i.e., response inhibition, set shifting, attentional disengagement) relative to individuals without any psychiatric diagnoses. additionally, the investigators will examine whether these deficits are associated with self-report measures of rnt as well as in vivo responding during a laboratory paradigm designed to induce intrusive thinking. findings could inform psychological treatment of these problematic intrusions using novel transdiagnostic approaches.

Eligibility criteria:
inclusion criteria: 1. adults (age 18+) 2. intrusive thoughts group: clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score above the clinical mean (≥ 37) on the trait repetitive negative thinking measure (perseverative thinking questionnaire, ptq) 3. non-psychiatric control (npc) group: a score 1 sd below the community mean (≤ 15) on the trait repetitive negative thinking measure (ptq) 4. sufficient fluency of english to understand study procedures and questionnaires 5. ability to provide informed consent. 6. comfortable and capable of using a computer and completing reaction-time tasks. exclusion criteria: 1. acute psychosis, mania, or suicidality 2. diagnosis of post-traumatic stress disorder (ptsd; in order to preserve diagnostic clarity of the domains of intrusive thoughts under investigation) 3. serious neurological disorder or impairment (e.g., brain damage, blindness), attention deficit hyperactivity disorder (adhd), intellectual disability, or autism.

Keywords: ocd gad mdd rumination obsession worry
a study to investigate the effectiveness of ah234844 (lavoltidine) compared with nexium and ranitidine.

Conditions: Gastroesophageal Reflux Disease; Reflux, Gastroesophageal

Summary: current treatment for gastroesophageal reflux disease (gerd) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression. clinical data on ah234844 demonstrates a rapid onset of action, high potency, and prolonged duration of effect. the present study endeavors, in part, to compare lavoltidine to two gerd drugs, nexium and ranitidine.

a three-part study in healthy male volunteers to determine the most effective of four different lavoltidine doses on gastric ph and to compare the most effective dose with nexium (esomeprazole) 40mg for the inhibition of gastric-acid secretion and with ranitidine (300mg/day) for the amount of pharmacodynamic tolerance

Eligibility criteria:
inclusion criteria: * subject must have a body mass index (bmi) from 19-30 kg/m2 * subject does not present with abnormal clinical lab findings * subject is able to tolerate a nasogastric ph electrode. exclusion criteria: * subject is helicobacter-positive on a c13 urea breath test * subject has a baseline median 24-hour gastric ph\>3 * for part b of the study, subjects are cyp 2c19 poor metabolizers.

Keywords: tolerance pharmacodynamics ranitidine esomeprazole pharmacokinetics gastroesophageal reflux disease (gerd) ah23844
early or late foley removal after thoracotomy

Conditions: Urinary Tract Infections

Summary: is the early removal of foley catheter safe in patients undergoing general thoracic surgery with an epidural catheter in place?

we hypothesis that removing the foley catheter within 48 hours after a thoracotomy in patients that have an epidural catheter will result in an increase in the rate of urinary infections and the need for reinsertion of the foley. we have designed a randomized trial to test this hypothesis.

Eligibility criteria:
inclusion criteria: * epidural catheter after thoracic surgery * foley in place exclusion criteria: * \< 18 years of age * death in hospital within 30 days of the operation * length of hospital stay is less than 48 hours * epidural catheter is removed before the 3rd postoperative day * patients who have a suprapubic catheter or no bladder * patients who require a urologist or a urologic technician to insert the foley catheter at the time of surgery * patients who were being intermittently catheterized before surgery * patients with a known urinary tract infection preoperatively * patients required to keep foley in since they required close monitoring of urinary output

Keywords: urinary bladder urinary catheterization epidural analgesia catheters, indwelling
stimulation of parieto-hippocampal connectivity in patients with major depressive disorder

Conditions: Depression; Depressive Disorder; Depressive Episode; Depressive Disorder, Major

Summary: this study aims to investigate the effects of individualized repetitive transcranial magnetic stimulation (rtms) of parieto-hippocampal functional connectivity in patients with major depressive disorder (mdd). specifically, patients will be randomized to one of three groups and will receive 15 days of rtms over three weeks. each day they will receive one active session of rtms over the dorsolateral parietal cortex (dlpfc) and depending on group assignment another session either a) active rtms over dlpfc, b) active rtms over left and right lateral parietal cortex (lpc), or c) sham rtms over dlpfc or lpc. stimulation targets in the lpc will be individualized for each patient based on their resting-state functional connectivity between the hippocampus and lpc. clinical, neuropsychological and fmri data will be acquired before and after the treatment course.


Eligibility criteria:
inclusion criteria: * fulfilled criteria for unipolar major depressive disorder for at least four weeks * did not respond to a minimum of one or did not tolerate a minimum of two antidepressants in the current episode exclusion criteria: * metal in the brain or the skull * cardiac pacemaker or intracardiac lines * medication infusion devices * heart or brain surgery * pregnancy * substance induced depression * history of substance abuse * psychotic episodes * bipolar disorder * anorexia * posttraumatic stress disorder (current or within the last 12 months) * claustrophobia * any condition resulting in increased intracranial pressure * traumatic brain injury * history of epilepsy * cerebral aneurysms * dementia * morbus parkinson * chorea huntington * multiple sclerosis * stroke or transient ischemic attack (within the last 2 years) * previous antidepressive treatment with rtms, electroconvulsive therapy (within the last 3 months), vagus nerve stimulation or deep brain stimulation

Keywords: repetitive transcranial magnetic stimulation theta burst stimulation rtms tbs resting-state fmri functional connectivity
safety, tolerability and immunogenicity of nbp607qiv in healthy adult volunteers

Conditions: Influenza

Summary: this study assesses safety, tolerability and immunogenicity of nbp607qiv to agrippal which are indicated for active immunization for the prevention of influenza disease.

subjects are randomly assigned in a 1:1 ratio to nbp607qiv versus agrippal s1. to assess the safety, solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination are assessed and reported. to assess the immunogenicity, antibody levels are evaluated by hemagglutination inhibition(hi) assay from sera obtained at pre-vaccination and 21 days post-vaccination.

Eligibility criteria:
inclusion criteria: 1. healthy adults aged 19 to 59 years 2. those who are able and willing to give written informed consent to study participation and compliance with study instructions after being informed of and understand details of the study 3. if female, at least 2 years after post- menopausal and negative result of urine-human chorionic gonadotropin (hcg) test at screening exclusion criteria: 1. those with hypersensitivity to any component of the study medication or chemically related substances, such as allergy to eggs or egg products 2. those with immunodeficiency disease 3. those with history of hypersensitivity when vaccination, such as guillain-barre syndrome 4. those who are contraindicated for intramuscular injection due to thrombocytopenia or coagulopathy 5. those who experienced fever (\>38°c) within the past 24 hours or any acute respiratory infection 6. those with history of treatment with any of immunosuppressants or immunomodulators within the past 3 months 7. those with history of receiving blood products or immunoglobulin within the past 3 months 8. those with history of influenza vaccination within the past 6 months 9. those who received another vaccine within the past 1 month or have plan to receive another vaccine within 1 months following the study vaccination 10. those with history of participation on another clinical trial within 1 month prior to the study vaccination 11. those with history of blood donation within 1 week prior to the study vaccination or plan of blood donation within 7 days following the study vaccination 12. those with any chronic diseases that interfere with the clinical trial or malignant tumors 13. pregnant or breastfeeding 14. those with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or might interfere with the safety of the study subject.
506u78 in relapsed or refractory acute lymphoblastic leukemia (t-all)

Conditions: T-ALL, T-NHL (Lymphoblastic)

Summary: the purpose of this study is to determine whether nelarabine is effective in the treatment of patients with t-all/nhl in order to achieve a complete remission followed by an early stem cell transplantation.


Eligibility criteria:
inclusion criteria: * t-all; t-nhl * age \>= 18 years * cytological treatment failure / relapse * molecular treatment failure / relapse * no promising therapy alternatives with approved medication available * no cns-manifestation, requiring intrathecal therapy or cns-radiation * no convulsive disease or neurotoxicity \> grade iii in patients history * written informed consent * no cytostatic therapy in the last 10 days * no pregnancy or breastfeeding * effective contraception * recovery of toxicities of previous chemotherapy - except leukemia- related changes like bone marrow suppression or pathological transaminases in liver manifestation exclusion criteria: * severe psychiatric illness * uncontrolled or severe cardiac disease or infection * active secondary neoplasms - except skin cancer (no melanoma)
fluorescence cystoscopy and optimized mmc in recurrent bladder cancer (finnbladder 9)

Conditions: Bladder Cancer

Summary: bladder cancer (bc), the second most common urological malignancy, is an important public health issue. one of the main challenges in the treatment of bladder cancer if the prevention of recurrences of non-invasive tumors, which is also associated with significant costs. the current study will investigate optimal treatment of patients with bladder cancer with high risk of tumor recurrence but low risk of progression. the main interest is comparison of photodynamic (pdd) bladder tumor resection (tur-br)to traditional tur-bt. also the efficacy of adjuvant optimized mitomycin-c is compared to patients with no adjuvant treatment.


Eligibility criteria:
inclusion criteria: - primary papillary bladder cancer at high risk for further recurrence as defined as follows: number of primary tumors ≥2, or size of solitary primary tumor ≥ 3 cm, or recurrent papillary tumors * histologically proven ta bladder cancer * histological grade 1-2 (who 1973 grading system) or papillary urothelial neoplasm of low malignant potential (punlmp) or low grade (who 2004 grading system) bladder cancer * written informed consent is required from every eligible patient exclusion criteria: * grade 3 tumors (who 1973 grading system), or high grade tumors (who 2004 grading system) * cis (carcinoma in situ) * suspicion or evidence of papillary tumors or cis of the upper urinary tract * non-tcc (transitional cell carcinoma, i.e. urothelial carcinoma) bladder cancer * suspicion or previous history of the patient not tolerating intravesical instillations * known allergy to mmc or hexaminolevulinate (hal, hexvix®) * urethral stricture, stone disease, chronic urinary tract infection or any other urological condition that may compromise study participation (as judged by treating physician) * pregnancy or lactating patient * other non-cured malignancy (excepting skin basalioma or cancer in situ of the cervix uteri or any other malignancy in remission ≥5 years) * age \< 18 years * expected survival time less than one year * expected poor compliance (e.g. some severe psychiatric disorders, antisocial behaviour, or dementia)

Keywords: bladder cancer recurrence photodynamic diagnosis pdd cost analysis
hope against cancer recurrence in hcc

Conditions: Liver Transplantation; HCC; Oncological Outcomes

Summary: liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (hcc), in patients with impaired liver function due to cirrhosis. a shortcoming, however, is tumor recurrence after transplantation. approximately 15 % of patients receiving livers develop recurrence and this depends on the quality of the liver received. machine liver perfusion, for example, hypothermic oxygenated liver perfusion (hope), which means that the organ is perfused with an oxygen-rich fluid in a cold environment before transplantation, is a novel method to improve the quality of livers before implantation. the standard of care is cold storage without perfusion. the objective of this study is to compare the survival after tumor recurrence of patients after liver transplantation for hcc between perfused and not perfused livers. this study's hypothesis is that survival without tumor recurrence is improved when the liver is perfused before implantation. the study involves transplant centers worldwide, and adults with hcc waiting for liver transplantation are included. 220 patients will be recruited within 12 months and then observed for at least 2 years after transplantation. to provide the most valid results, the patients will be randomly allocated to either the organ perfusion group or a control group with standard-of-care cold storage of the organ.


Eligibility criteria:
inclusion criteria: * adult recipients (\>18y), listed for liver transplantation with documented hcc (liver imaging reporting and data system (lirads) 5 lesion in magnetic resonance imaging or computer tomography of the liver or biopsy proven), * within up to seven criteria, i.e. hcc with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time point of liver transplantation, * written informed consent for the trial. this also includes patients beyond the up to seven criteria after successful downsizing of the hcc exclusion criteria: * donation after circulatory death (dcd) liver grafts * combined liver transplants * partial liver transplants * combined or mixed hepatocellular cholangiocarcinoma (chcc-ccc) or pure cholangiocarcinoma or other malignancies in histopathology of the liver explant * systemic antitumoural medical treatment with checkpoint inhibitors or multikinase inhibitors * post-transplant treatment with mtor inhibitors * acute and unexpected medical contraindications * pregnancy * cold storage time of \> 10 hours (both study arms)

Keywords: hope randomised controlled trial multicentre hepatocellular carcinoma liver transplantation
a phase ii , placebo-controlled study to assess efficacy of 28 day oral azd9668 in patients with bronchiectasis

Conditions: Bronchiectasis

Summary: the purpose of this study is to investigate if treatment with azd9668 for 28 days is effective in treating bronchiectasis (brx) and if so how it compares to placebo (a substance which does not have any action).


Eligibility criteria:
inclusion criteria: * female of non child bearing potential * clinical diagnosis of bronchiectasis * be sputum producers, with history of chronic expectoration on most days exclusion criteria: * concomitant diagnosis of pulmonary disease other than bronchiectasis or copd * fev1 of \<30% of predicted normal

Keywords: bronchiectasis phase ii
database study on patients with pcos

Conditions: Hirsutism; PCOS

Summary: all newly referred patients with pcos and hirsutism are listed in a database.

all premenopausal women referred to the outpatient clinic at the department of endocrinology from 1997 and onward with the referral diagnoses hirsutism and/or pcos are included in a clinical database. the patients should fulfill the rotterdam criteria for pcos or have clinical/biochemical hyperandrogenemia. routine evaluation include medical history, clinical examination, transvaginal ultrasound (us), and fasting blood samples. cycle history is recorded in all patients using a standard scheme prepared for hirsute patients. blood tests include androgens, lh, fsh, prolactin, and lipid profile. ogtt and acth are performed in high risk patients

Eligibility criteria:
inclusion criteria: * premenopausal * hirsutism or pcos
arthrocentesis alone versus arthrocentesis with hyaluronic acid injection

Conditions: Temporomandibular Joint Dysfunction Syndrome; Arthrocenteses; Hyaluronic Acid

Summary: comparison between arthrocentesis alone arthrocentesis with hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction.

temporomandibular joint (tmj) anterior disc displacement (add) is one of the most common tmj disorders.it can occur in all age groups, with a high prevalence in adolescents . add often presents with clicking, joint pain, a limited range of mouth opening. furthermore,add might lead to osteoarthrosis . since add of the tmj can lead to various harmful outcomes, how to manage add is considered a key problem for most tmj experts. it has been difficult for most clinicians to select a suitable method for add patients with different grades of severitis ). initially, these conditions can be managed conservatively by employing techniques such as occlusal splint therapy, physiotherapy, pharmacotherapy and occlusal treatments. if medical treatment fails, minimally invasive (sodium hyaluronate or corticosteroid infiltrations and arthrocentesis) and invasive treatments (arthroscopy, arthroplasty, arthrotomy, discectomy, condylotomy) are formed ). sodium hyaluronate is a buffered solution of hyaluronate acid sodium salt, which is an essential component of the cartilage.it acts against the disintegration of the extracellular matrix.it reduces friction, and it features an anti-inflamatory effect. it is indicated for the treatment of osteoarthritic symptoms and inflammatory degenerative joint disease). intra-articular hyaluronic acid injection provides long-term palliative effects on symptoms and signs of tmj pain .

Eligibility criteria:
inclusion criteria: * adults with age between( 18-45) years * both genders * the cases ciinically have either of ( limitation of mouth opening , pre-auricular pain , headache, temporal, and occipital tenderness ) and radiologically (mri) diagnosed as add with reduction * the patients have symptom durations for more than 3 months with medical treatment. * patients whom did not respond to medical treatment exclusion criteria: * previous tmj surgery or previous arthrocentesis. * patients with arthritis or history of condylar trauma * patients with degenerative change of the condylar head and with facial asymmetry, retrognathism, or prognathism * severe co-morbid conditions (uncontrolled diabetes, hypertenion
extended use of sodium bicarbonate in patients with cancer

Conditions: Malignant Neoplasm

Summary: this pilot phase i trial studies the safety of long-term use of sodium bicarbonate in patients with cancer. sodium bicarbonate may neutralize tumor acidity and as a result may inhibit the spread of the tumor to other parts of the body (metastases) and improve survival.

primary objectives: i. determine if the dose concentration of 0.5 g/kg/day sodium bicarbonate is feasible and well tolerated as measured by the proportion of subjects with first evidence of adherence failure. secondary objectives: i. determine if the dose concentration of 0.5 g/kg/day sodium bicarbonate is safe for long term consumption (90 days) as measured by blood pressure, resting pulse rate, and basic metabolic panels to assess metabolic alkalosis. outline: phase i (run-in/adjustment): patients receive sodium bicarbonate orally (po) dissolved in water thrice daily (tid) or twice daily (bid) on days 1-10. the dose may be adjusted as necessary. phase ii (long term): patients continue to receive sodium bicarbonate po tid or bid for a total of 90 days in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * any cancer patient enrolled in the study must have a written approval from their oncologist that a notation will be made in the patient's chart for their study participation * subject without known cognitive impairment, central nervous system (cns) metastasis, overt psychosis, major depression, or delirium as noted in the oncology medical record * subject with a karnofsky performance status scale of 80% or greater at time of consent * subject has completed initial adjuvant therapy and is not currently receiving or waiting to receive chemotherapy during the next 120 days * breast cancer subjects may be enrolled if they are receiving hormonal blockade therapy * subject is not enrolled in any other clinical trials * subject has a valid working phone number to be contacted with during the study * subject must be willing to provide urine specimen for ph measurements during scheduled clinical visits * subject must be willing to provide a 3 ml blood sample for metabolic panels during scheduled clinical visits * subject does not have uncontrolled hypertension (systolic pressure \> 140, diastolic pressure \> 90) despite maximal anti-hypertensive therapy * subject has healthy renal function: creatinine clearance: 88-128 ml/min; glomerular filtration rate (gfr): \> 90 ml/min/1.7m\^2 based on standard care results no older than 2 weeks; if no data exist, the subject will need to consent to a blood draw for a basic metabolic panel (which measures creatinine) for verification * subject must be informed of the investigational nature of this study and must sign and written informed consent in accordance with institutional and federal guidelines * subject is not pregnant or breastfeeding at time of consent; a pregnancy test will be conducted from urine sample on day of consent in premenopausal women * subject agrees to use medically approved contraception (ie. condoms, oral contraceptive) if premenopausal

Keywords: tumor acidity